跨性别医疗:代谢结局与心血管风险
本文采用叙述性综述方法,汇总跨性别者接受性别肯定激素治疗(GAHT)期间的代谢与心血管结局证据,并提出随访监测建议。现有数据显示跨性别队列中2型糖尿病风险未增加,但男性化GAHT增加去脂体重,女性化GAHT与更高脂肪量和胰岛素抵抗相关;跨性别队列心血管疾病风险升高,尤其女性化GAHT期间。
要点
- 跨性别队列中2型糖尿病风险未增加,但男性化GAHT增加去脂体重,女性化GAHT与更高脂肪量及胰岛素抵抗相关。
- 跨性别队列心血管疾病风险升高,尤其女性化GAHT期间;男性化GAHT与更不利血脂谱、更高血细胞比容和血压升高相关,女性化GAHT与促凝血改变和更低HDL胆固醇相关。
- 出生时指定男性性别、启动GAHT时年龄较高和使用醋酸环丙孕酮是不良心血管疾病标志物的独立危险因素。
核心结论
- 现有数据未显示跨性别队列中2型糖尿病风险增加,但跨性别队列心血管疾病风险升高,尤其女性化GAHT期间。
- GAHT应按个体危险因素(即药物、剂量和给药形式)个体化,医生需讨论生活方式和预防性药物以改善GAHT期间的代谢和心血管疾病风险。
- 随访项目必须涵盖常规心血管风险标志物,并应考虑生物学年龄和性别可能影响个体风险评估,包括心理健康、生活方式和新型心血管风险标志物。
研究设计与样本
- 采用叙述性综述方法,汇总跨性别者接受性别肯定激素治疗(GAHT)期间代谢与心血管结局的证据,并提出随访监测建议。
主要发现
- 跨性别队列中2型糖尿病风险未增加。
- 男性化GAHT增加去脂体重;女性化GAHT与更高脂肪量和胰岛素抵抗相关。
- 跨性别队列心血管疾病风险升高,尤其女性化GAHT期间。
- 男性化GAHT与更不利血脂谱、更高血细胞比容和血压升高相关;女性化GAHT与促凝血改变和更低HDL胆固醇相关。
- 出生时指定男性性别、启动GAHT时年龄较高和使用醋酸环丙孕酮是不良心血管疾病标志物的独立危险因素。
临床怎么用
- GAHT应按个体危险因素(即药物、剂量和给药形式)个体化。
- 医生需讨论生活方式和预防性药物,以改善GAHT期间的代谢和心血管疾病风险。
- 随访项目必须涵盖常规心血管风险标志物,并应考虑生物学年龄和性别可能影响个体风险评估,包括心理健康、生活方式和新型心血管风险标志物。
- 代谢和心血管疾病结局可能因少数群体压力减少、生活方式改善和更密切监测导致预防性药物(如他汀类)优化而在性别肯定医疗期间改善。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transgender identity is often associated with gender dysphoria and minority stress. Gender-affirming hormone treatment (GAHT) includes masculinising or feminising treatment and is expected to be lifelong in most cases. Sex and sex hormones have a differential effect on metabolism and CVD in cisgender people, and sex hormone replacement in hypogonadism is associated with higher vascular risk, especially in ageing individuals. Using narrative review methods, we present evidence regarding metabolic and cardiovascular outcomes during GAHT and propose recommendations for follow-up and monitoring of metabolic and cardiovascular risk markers during GAHT. Available data show no increased risk for type 2 diabetes in transgender cohorts, but masculinising GAHT increases lean body mass and feminising GAHT is associated with higher fat mass and insulin resistance. The risk of CVD is increased in transgender cohorts, especially during feminising GAHT. Masculinising GAHT is associated with a more adverse lipid profile, higher haematocrit and increased BP, while feminising GAHT is associated with pro-coagulant changes and lower HDL-cholesterol. Assigned male sex at birth, higher age at initiation of GAHT and use of cyproterone acetate are separate risk factors for adverse CVD markers. Metabolic and CVD outcomes may improve during gender-affirming care due to a reduction in minority stress, improved lifestyle and closer surveillance leading to optimised preventive medication (e.g. statins). GAHT should be individualised according to individual risk factors (i.e. drug, dose and form of administration); furthermore, doctors need to discuss lifestyle and preventive medications in order to modify metabolic and CVD risk during GAHT. Follow-up programmes must address the usual cardiovascular risk markers but should consider that biological age and sex may influence individual risk profiling including mental health, lifestyle and novel cardiovascular risk markers during GAHT.
引用
- Glintborg D, Christensen LL, Andersen MS, et al. Transgender healthcare: metabolic outcomes and cardiovascular risk. Diabetologia. 2024. PMID: 38958699. doi:10.1007/s00125-024-06212-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。